Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements
I'm PortAI, I can summarize articles.
Silexion Therapeutics Corp. has published a shareholder letter from CEO Ilan Hadar, highlighting major achievements in 2025, including positive preclinical data for SIL204 and completion of regulatory toxicology studies. The letter also mentions positive feedback from Germany’s Federal Institute for Drugs and Medical Devices on the Phase 2⁄3 trial design and outlines plans to initiate a Phase 2⁄3 clinical trial in locally advanced pancreatic cancer in early 2026, along with expected milestones for the upcoming year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments